Home » Topics » Disease categories and therapies » Inflammatory

Inflammatory
RSS

Bristol-Myers Squibb presents phase Ib data for anti-PD-L1 BMS-936559 in sepsis

March 1, 2018

Accro Bioscience divulges necrosis inhibitors

Feb. 16, 2018

Galecto Biotech discovers galectin inhibitors

Feb. 1, 2018

Blade Therapeutics identifies new calpain inhibitors

Jan. 29, 2018

BI-2545 shows promise for the unmet medical need in IPF treatment

Jan. 12, 2018

DS-28120313 shows in vivo efficacy as a potent orally active hepcidin production inhibitor

Dec. 13, 2017

Cardiac Hsl gene knockdown provides model of hypoxia tolerance

Dec. 1, 2017

Bristol-Myers Squibb initiates phase I trial of BMS-986235 in healthy subjects

Nov. 24, 2017

Spingotec Therapeutics divulges DPP3 inhibitors

Nov. 22, 2017

First-in-human results provided for TR-Pharm's anti-interleukin-1 biologic RPH-104

Nov. 15, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...